Chronic lymphocytic leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BTK 26
• CD19 33
• BCL-2 10
• TP53 3
• CD20 10
• CD22 6
• ABL1 2
• PI3K 1
• NOTCH1 0
• CXCR4 0
• STAT3 0
• CD123 1
• CD38 1
• HMGB1 0
• PD-1 0
• PD-L1 0
• EGFR 0
• HDAC 0
• MDM2 0
• PPAR 0
• TIM-3 0
• AKT 0
• ALK 0
• ATM 0
• BCMA 1
• BDNF 0
• BRAF 0
• BRD4 0
• CD30 0
• CD47 0
• CSF1R 1
• CTNNB1 0
• ERK 0
• FAK 0
• FLT3 0
• IDH 0
• IL-23 0
• IL-4 0
• KMT2A 0
• MAPK 0
• MMP-9 0
• NLRP3 0
• NRAS 0
• PCSK9 0
• PRMT5 0
• TLR4 0
• VEGF 0

5 of 5+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, United States· US$390,447 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Rationally directed therapy for CLL

  University of Tx Md Anderson Can Ctr· Houston, United States· US$690,011 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Integrating AI and Deep Mutational Scanning to Predict the Cancer-Promoting Effect of Shelterin Mutations

  University of California Berkeley· Berkeley, United States· US$2,197,943 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · R41

  Development of MCL 1-Targeting Antibody–Drug Conjugates for Cancer Therapy

  Immunogenic Cancer Engineering Therapeutics Llc· Englewood Cliffs, United States· US$412,351 awarded in fiscal year 2026· until Aug 2027

• NIH NEI · R01

  Discovery of novel trifunctional hybrid compounds (TFHCs): potential glaucoma therapy with superior IOP reduction and neuroprotection

  Creighton University· Omaha, United States· US$576,730 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Signaling and Powering Anti-cancer Responses in T Cells SPARC

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €2,500,000· until Oct 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Immuno-Modulatory Platform for Advanced CLL Therapy (IMPACT)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €150,000· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting GAB1: a novel therapeutic strategy for the treatment of leukemias (LeukemiaBlock)

  Masarykova univerzita· Brno, Czechia· EU contribution €150,000· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A single-cell-based solution for an early diagnosis of Richter transformation in patients with chronic lymphocytic leukemia (earlyRTdx)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €150,000· until Oct 2027

10 of 143 running projects, newest first. Listed amounts together: US$97.4m + €16.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

  NCT04477291· Aptose Biosciences Inc.· Updated 7 Mar 2025

  “Change in corporate strategy”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 3
• Metabolomics 1
• Mass Spectrometry 2
• Flow Cytometry 21
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 9
• Magnetic Resonance Imaging 4
• Machine Learning 10
• Cohort Studies 18
• Genome-Wide Association Study 2

• Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care.

  Support Care Cancer, Sept 2026

• Integrated analysis of IGHV rearrangements and cytogenetic abnormalities in a large chronic lymphocytic leukemia cohort (CLL-POL1).

  BMC Cancer, Jun 2026

• Pure Nodal Small Lymphocytic Lymphoma: Clinical, Pathologic, and Outcome Features in a Single-Center Cohort.

  Medicina (Kaunas), Jun 2026

• IGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis.

  Ann Hematol, Jun 2026

• Risk of Skin Cancer Among Patients With Chronic Lymphocytic Leukemia.

  JAMA Dermatol, May 2026

• Real-World Treatment Patterns and Safety Outcomes of Targeted Therapies in a Single-Center Chronic Lymphocytic Leukemia Cohort.

  Medicina (Kaunas), Apr 2026

• Cardiovascular Disease Risk in Adults With Hematological Malignancies: A Population-Based Cohort Study Using Linked Databases.

  J Am Coll Cardiol, Apr 2026

• Pretreatment immunoglobulin profiles and survival outcomes in hematologic malignancies and autoimmune cytopenias: a comparative cohort analysis.

  BMC Immunol, Feb 2026

• Subsequent risk of non-keratinocyte skin cancers in adult cancer survivors: a SEER-based cohort study.

  BMJ Open, Jan 2026

• Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data.

  J Manag Care Spec Pharm, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.